MLTX: Rounding Bottom detected on 9 Apr 2026

MLTX is forming a rounding bottom pattern as MoonLake's clinical-stage biotech stock recovers from depressed levels following September 2025 Phase 3 trial disappointment. At $18.60, price sits 212.61% above 52-week lows, yet -70.36% below 52-week highs, suggesting substantial mean reversion opportunity. The pattern structure scores a strong 15/15, with tight volume confirmation (12/12) and moderate breakout momentum (10.4/13). Volume relative strength of 1.5x average amplifies conviction. Current RSI of 57.81 signals neither overbought nor oversold conditions, while positive MACD histogram (0.0445) reinforces upside bias. Key resistance near $53.57 represents 188% upside; critical support anchors at $5.95. Overall quality score of 76.4 indicates solid technical foundation.

Cormorant Asset Management bought $27.86 million of MLTX in February 2026, lifting the position to 2.65% of its portfolio, signaling institutional conviction at depressed valuations. The FDA indicated that existing MIRA, VELA-1, and VELA-2 trial data for sonelokimab in hidradenitis suppurativa may be sufficient to support a BLA submission in H2 2026, with no additional HS clinical trials required. This significantly de-risked regulatory pathway. Week 40 Phase 3 VELA data released March 28, 2026 showed 62% of patients achieved HiSCR75 response with up to 32% achieving HiSCR100, validating long-term efficacy. MoonLake ended 2025 with $394 million cash and secured up to $400 million in additional non-dilutive Hercules Capital funding. 12 analysts rate MLTX a Buy consensus as of April 1, 2026. Pattern timing aligns with post-data relief and institutional accumulation phase.

Successful rounding bottom breakout targets $19.84 (conservative measured move), with potential to extend toward $53.57 resistance on sustained volume >1.5M shares daily. Win probability of 63.62% suggests >2:1 risk-reward setup. Volume confirmation remains critical—any daily close above $19.84 on elevated volume (>1.5x) would signal pattern completion. Break of 52-week high ($62.60) sits within realm of possibility given biotech sector strength and bullish regime (0.87 score). Invalidation occurs decisively below $5.95 support; loss of that level ends the setup entirely. ATR of 1.24 (6.67% of price) provides adequate swing range for position management within 1-3 month timeframe.

Key catalysts include upcoming SLK readouts in axial spondyloarthritis and psoriatic arthritis, with execution risks on HS BLA package and clinical risk in non-HS programs. The company faces reliance on single lead asset SLK amid increased competition and potential safety/efficacy concerns during pivotal trial phases. BLA submission expected May 1, 2026—regulatory delays or qualification issues pose material downside. No revenue-stage clinical biotech faces inherent execution risk; multiple 2026 catalysts (52-week VELA readout Q2, IZAR-1 PsA results mid-2026, IZAR-2 readout H2 2026) create binary event risk. Beta of 0.66 provides relative downside cushion, but biotech sector volatility remains elevated. Funding dilution risk noted given capital intensity of later-stage trials.